

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08550		Serial No.: 10/786,774	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Joseph Holoshitz <i>et al.</i>			
(37 CFR § 1.98(b))				Filing Date: 02/25/04		Group Art Unit: 1649	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
SS	1	4,552,891	11/12/85	Ho <i>et al.</i>	514	443	9/13/83
SS	2	4,588,394	05/13/86	Schulte <i>et al.</i>	604	9	03/16/84
SS	3	4,902,505	2/20/90	Pardridge <i>et al.</i>	424	85.7	4/25/88
SS	4	5,004,697	4/02/91	Pardridge	436	547	8/17/87
SS	5	5,051,448	9/24/91	Shashoua	514	547	5/07/90
SS	6	5,130,129	7/14/92	Pardridge	424	85.8	3/06/90
SS	7	5,147,855	9/15/92	Gozes <i>et al.</i>	514	12	7/07/89
SS	8	5,166,320	11/24/92	Wu <i>et al.</i>	530	395	04/02/90
SS	9	5,169,862	12/08/92	Burke <i>et al.</i>	514	450	11/18/91
SS	10	5,192,746	3/09/93	Lobl <i>et al.</i>	514	11	7/09/90
SS	11	5,354,844	10/11/94	Beug <i>et al.</i>	530	345	03/09/90
SS	12	5,393,773	2/28/95	Craig <i>et al.</i>	514	415	1/19/92
SS	13	5,525,727	6/11/96	Bodor	546	39	10/28/92
SS	14	5,539,085	7/23/96	Bischoff <i>et al.</i>	530	350	8/20/93
SS	15	5,554,639	9/10/96	Craig <i>et al.</i>	514	415	6/02/95
SS	16	5,559,103	9/24/96	Gaeta <i>et al.</i>	514	54	7/20/94
SS	17	5,576,423	11/19/96	Aversa <i>et al.</i>	530	388.75	12/02/94
SS	18	5,601,835	2/11/97	Sabel <i>et al.</i>	424	424	1/12/94
SS	19	5,618,803	4/08/97	Bodor	514	81	11/15/94
SS	20	5,643,207	07/01/97	Rise	604	93	06/27/96
SS	21	5,624,894	4/29/97	Bodor	514	2	4/27/95
SS	22	5,670,477	9/23/97	Poduslo <i>et al.</i>	514	2	4/20/95
SS	23	5,801,161	9/01/98	Merkus	514	52	6/17/96
SS	24	5,864,037	1/26/99	Chasin <i>et al.</i>	544	118	6/06/96
SS	25	5,869,479	2/09/99	Kreutner <i>et al.</i>	514	212	8/14/97
SS	26	5,972,883	10/26/99	Gozes <i>et al.</i>	514	12	3/30/95
SS	27	6,042,579	03/28/00	Elsberry <i>et al.</i>	604	891.1	04/30/97
SS	28	6,117,454	9/12/00	Kreutner <i>et al.</i>	424	490	5/27/97
SS	29	6,132,764	10/17/00	Li <i>et al.</i>	424	450	4/08/96
SS	30	6,153,193	11/28/00	Kabanov <i>et al.</i>	424	184.1	6/07/95
SS	31	6,172,277	01/09/01	Tate <i>et al.</i>	800	12	10/28/97
SS	32	6,179,826	1/30/01	Aebischer <i>et al.</i>	604	522	10/29/96
SS	33	6,153,200	11/2000	Carson <i>et al.</i>	424	201.1	

Examiner: <i>SS</i>	Date Considered: 11/11/06
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08550	Serial No.: 10/786,774			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Joseph Holoshitz <i>et al.</i>				
(37 CFR § 1.98(b))				Filing Date: 02/25/04	Group Art Unit: 1649			
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
SS	34	WO 97/34002	18.09.97	WIPO	A61K	37/02		
SS	35	WO 90/14835	13.12.90	WIPO	C12N	15/31		
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
SS	36	Auger I <i>et al.</i> , "HLA-DR4 and HLA-DR10 Motifs That Carry Susceptibility To Rheumatoid Arthritis Bind 70-kD Heat Shock Proteins," <i>Nature Med</i> 2:306-310 (1996)						
SS	37	Basu S. <i>et al.</i> , "CD91 is a common receptor for heat shock proteins gp96, hsp70, and calreticulin," <i>Immunity</i> 14: 303-313 (2001)						
SS	38	Benvenisty and Reshef, "Direct introduction of genes into rats and expression of the genes" <i>Proc. Nat. Acad. Sci. USA</i> , 83:9551-55 (1986)						
SS	39	Bickel <i>et al.</i> , "Pharmacologic effects <i>in vivo</i> in brain by vector-mediated peptide drug delivery," <i>Proc. Natl. Acad. Sci. USA</i> 90:2618-2622 (1993)						
SS	40	Borisova <i>et al.</i> , "Behavior of a Short preS1 Epitope on the Surface of Hepatitis B Core Particles," <i>Biol Chem</i> 380:315-324 (1999)						
SS	41	Colaco CB <i>et al.</i> , "Deficient repair of O ⁶ -methylguanine in lymphocytes from rheumatoid arthritis families may be and acquired defect," <i>Clin Exp Immunol</i> 72:15-19 (1988)						
SS	42	Corder EH <i>et al.</i> , "Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families," <i>Science</i> 261:921-923 (1993)						
SS	43	Corder EH <i>et al.</i> , "Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease," <i>Nat Genet</i> 7:180-184 (1994)						
SS	44	Curran M <i>et al.</i> , "HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease," <i>NeuroReport</i> 8:1467-1469 (1997)						
SS	45	Dubensky <i>et al.</i> , "Direct transfection of viral and plasmid DNA into the liver or spleen of mice," <i>Proc. Nat. Acad. Sci. USA</i> , 81:7529-33 (1984)						
SS	46	Eldred <i>et al.</i> , "Orally Active Non-Peptide Fibrinogen Receptor (GpIb/IIa) Antagonists: Identification of 4-[4-(4-Aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic Agent," <i>J. Med. Chem.</i> 37:3882 (1994)						
SS	47	Fisher <i>et al.</i> , "(±)-cis-2-Methyl-spiro (1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M ₁ agonist attenuates cognitive dysfunctions in AF64A-treated rats," <i>Neurosci Lett</i> 102:325-331 (1989)						
SS	48	Forsythe and Westbrook, "Slow Excitatory Postsynaptic Currents Mediated By N-Methyl-D-Aspartate Receptors On Cultured Mouse Central Neurons," <i>J Physiol (Lond)</i> 396:515-533 (1988)						
SS	49	Galea E and Feinstein DL, "Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP," <i>FASEB J</i> 13:2125-2137 (1999)						
SS	50	Greengersen PK <i>et al.</i> , "The Share Epitope Hypothesis: An Approach to Understanding The Molecular Genetics of Susceptibility to Rheumatoid Arthritis," <i>Arthritis Rheum</i> 30:1205-1213 (1987)						
SS	51	Ku <i>et al.</i> , "Potent Non-peptide Fibrinogen Receptor Antagonists Which Present An Alternative Pharmacophore," <i>J. Med. Chem.</i> 38:9 (1995)						
SS	52	Levitzi A., "Targeting signal transduction for disease therapy," <i>Curr Opin Cell Biol</i> 8:239-244 (1996)						
SS	53	Linden <i>et al.</i> , "Characterization of Human A _{2B} Adenosine Receptors: Radioligand Binding, Western Blotting, and Coupling to G _q in Human Embryonic Kidney 293 Cells and HMC-1 Mast Cells," <i>Molecular Pharmacology</i> 56:705-713 (1999)						
SS	54	Lipman and Pearson, "Rapid and Sensitive Protein Similarity Searches," <i>Science</i> 227:1435-1441 (1985)						
SS	55	McCurdy D <i>et al.</i> , "Delayed Repair of DNA Damage by Ionizing Radiation in Cells from Patients with Juvenile Systemic Lupus Erythematosus and Rheumatoid Arthritis," <i>Radiat Res</i> 147:48-54 (1997)						
SS	56	Nepom GT <i>et al.</i> , "HLA Genes Associated With Rheumatoid Arthritis: Identification of Susceptibility Alleles Using Specific Oligonucleotide Probes," <i>Arthritis Rheum</i> 32:15-21 (1989)						
SS	57	Pearson and Lipman, "Improved tools for biological Sequence comparison," <i>Proc. Natl. Acad. Sci. (USA)</i> 85:2444-2448 (1988)						
SS	58	Pericak-Vance MA <i>et al.</i> , "Linkage Studies in Familial Alzheimer Disease: Evidence for Chromosome 19 Linkage," <i>Am J Hum Genet</i> 48:1034-1050 (1991)						
SS	59	Pumpens P and Grens E., "Hepatitis B core particles as a universal display model: a structure-function basis for development," <i>FEBS Lett</i> 442:1-6 (1999)						
Examiner:				Date Considered: 1/31/06				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08550	Serial No.: 10/786,774
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Joseph Holoshitz <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 02/25/04	Group Art Unit: 1649
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
SS	60	Stirttmatter WJ and Roses AD, "Apolipoprotein E and Alzheimer disease," <i>Proc Natl Acad Sci USA</i> 92:4725-4727 (1995)			
SS	61	Wagner, <i>et al.</i> , "Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells," <i>Proc. Natl. Acad. Sci.</i> , 88:4255-4259 (1991)			
SS	62	Weisgraber KH, "Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112," <i>J Lipid Res</i> 31:1503-1511 (1990)			
SS	63	Weyand CM <i>et al.</i> , "The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis," <i>Ann Intern Med</i> 117:10 801-806 (1992)			
SS	64	Wolff <i>et al.</i> , "Direct Gene Transfer Into Mouse Muscle in Vivo," <i>Science</i> , 247:1456-68 (1990)			
SS	65	Walker <i>et al.</i> , "Proteopathy: The next therapeutic frontier?," <i>Curr Opin Investig Drugs</i> , 3(5):782-787 (2002)			
SS	66	Fitjohn <i>et al.</i> , "Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein," <i>J. Neuroscience</i> , 21(13):4691-4698 (2001)			
SS	67	Chapman <i>et al.</i> , "Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice," <i>Nature Neuroscience</i> , 2:271-276 (1999)			
SS	68	Schenk <i>et al.</i> , "Potential treatment opportunities for alzheimer's disease through inhibition of secretases and A β immunization," <i>J. Mole. Neuroscience</i> , 17:259-267 (2001)			
SS	69	Perdrieger <i>et al.</i> , "Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis," <i>J. Rheumatology</i> , 24(7):1272-1276 (1997)			
SS	70	Auger <i>et al.</i> , "A function for the QKRAA amino acid motif: mediating binding of DnaJ to DnaK," <i>J. Clin Invest</i> , 99(8):1818-1822 (1997)			
SS	71	Singal <i>et al.</i> , "Genetics of rheumatoid arthritis (RA): two separate regions in the major histocompatibility complex contribute to susceptibility to RA," <i>Immunology Letters</i> , 69:301-306 (1999)			
SS	72	Vitolo <i>et al.</i> , "Amyloid β -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling," <i>PNAS</i> , 99(20):13217-13221 (2002)			
SS	73	Sun <i>et al.</i> , "Bilateral injection of isoproterenol into hippocampus induces alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat," <i>FEBS Letters</i> , 579:251-258 (2005)			
SS	74	Gong <i>et al.</i> , "Persistent improvement in synaptic and cognitive functions in an alzheimer mouse model after rolipram treatment," <i>J. Clin. Invest.</i> , 114(11):1624-1634 (2004)			
	75				
	76				
	77				
	78				
	79				
	80				
	81				
	82				
	83				
	84				
	85				
Examiner:				Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					